Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow-derived mesenchymal stem cells (University Hospital, Toulouse)
- Development stage
- Unknown
- Lead developer
- CHU de Toulouse
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intramyocardial
01
Overview
This investigational cell therapy consists of autologous bone marrow-derived mesenchymal stem cells (MSCs) developed by University Hospital, Toulouse. The therapy is specifically designed for patients with ischemic cardiomyopathy who are dependent on a Left Ventricular Assist Device (LVAD). The process involves harvesting the patient's own bone marrow, followed by a 17-day isolation and culture period conducted by the French Blood Establishment. The resulting MSCs are then delivered via intramyocardial injections during device surgery. The therapeutic goal is to stimulate cardiac regeneration and repair, thereby improving myocardial function to a level that allows the patient to be successfully weaned from mechanical circulatory support.
- Other names
- Autologous mesenchymal stem cellsMSCs for Weaning From LVADAutologous bone marrow-derived MSCs
Beyond the preview
Go deeper on autologous bone marrow-derived mesenchymal stem cells (University Hospital, Toulouse).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow-derived mesenchymal stem cells (University Hospital, Toulouse).